Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 76-0837053 (State or other jurisdiction of incor ...

Financial Data and Key Metrics Changes - Catalyst Pharmaceuticals reported an all-time high in total FIRDAPSE net revenue of $53 million for Q2 2022, representing a 57.7% increase compared to the same period last year [6] - Net income before income taxes for Q2 2022 was $28.2 million, a 77.6% increase compared to $15.9 million for Q2 2021 [7] - GAAP net income for Q2 2022 was $21.6 million, or $0.21 per basic share and $0.20 per diluted share, reflecting a 77.5% increase year-over-year [49] - The company ended Q2 2022 with $220.8 million in cash and investments and no funded debt [7][57] Business Line Data and Key Metrics Changes - FIRDAPSE net sales for Q2 2022 were $53 million, showing a 23.3% growth quarter-over-quarter and a 57.7% growth year-over-year [22] - The company successfully transitioned nearly 100% of adult LEMS patients from Ruzurgi to FIRDAPSE without a lapse in therapy [23] - Payer approval rates for adult LEMS patients transitioning from Ruzurgi were greater than 90% [24] Market Data and Key Metrics Changes - The company expects steady organic growth in the second half of 2022, primarily driven by new patient enrollments of already diagnosed LEMS patients not yet on FIRDAPSE [26] - Leading indicators for Q3 are positive, with July net new patients ahead of forecast due to low discontinuation rates and consistent new enrollments [27] Company Strategy and Development Direction - Catalyst Pharmaceuticals aims to broaden and diversify its product portfolio through collaborative partnerships and acquisitions of commercial stage assets [17] - The company is actively engaged in advanced stages of due diligence for several acquisition opportunities [18] - The company has made significant progress in building its ESG program, publishing its inaugural set of industry-specific disclosures [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, believing the company is well-positioned to execute its growth strategy and deliver long-term value for stakeholders [21] - The company anticipates that 2022 will continue to be a transformative year with increased momentum to diversify and invest in innovative opportunities for rare diseases [60] Other Important Information - The company resolved issues with Jacobus Pharmaceuticals, acquiring certain intellectual property rights, including U.S. and Mexico rights for Ruzurgi [12] - A supplemental new drug application for FIRDAPSE to support its use in pediatric LEMS patients has been accepted by the FDA for review [15] Q&A Session Summary Question: What are the key factors to achieve the upper end of revenue guidance? - Management indicated that strong new patient enrollments and low discontinuation rates are crucial for achieving the upper end of revenue guidance [64] Question: What information was provided to the FDA regarding the pediatric LEMS supplemental application? - The company submitted pediatric safety data and simulations on how adult data translates to pediatric patients [67] Question: Will potential business development activities be accretive to revenue opportunities next year? - Management expects that any potential business development activities would be accretive to revenues next year, leveraging established commercial infrastructure [68] Question: What is the expected pace of naïve new patient enrollments in the second half of the year? - Management expects the pace of growth to continue, with strong new enrollments and steady discontinuation rates [74] Question: What does the newly acquired patent cover? - The patent contains claims for a new and novel previously unknown impurity that appears in all products containing amifampridine [78]

Table of Contents Title of Each ClassTicker SymbolName of Exchange on Which Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Market Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File ...

| --- | --- | |------------------------------|-------| | | | | Dedicated To Making A | | | Meaningful Difference In The | | | Lives Of Patients | | | Suffering From Rare Diseases | | NASDAQ: CPRX May 2022 1 Confidential Safe Harbor 2 Confidential This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All statements regarding our strategy, future operations, financial position, estimated revenues or losses, project ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Ali Grande - Vice President, Chief Financial Officer and Treasurer Patrick McEnany - Chairman and Chief Executive Officer Jeff Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Joe Catanzaro - Piper Sandler Charles Duncan - Cantor Fitzgerald Les Sulewski - Truist Securities Scott Henry - ROTH Capital O ...

Table of Contents Title of Each ClassTicker SymbolName of Exchange on Which Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Market Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission Fil ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2021 Earnings Conference Call March 17, 2022 8:30 AM ET Company Participants Patrick McEnany - Co-Founder, Chairman, President and CEO Alicia Grande - VP, CFO and Treasurer Steven Miller - COO and Chief Scientific Officer Jeff Del Carmen - Chief Commercial Officer Gary Ingenito - Chief Medical and Regulatory Officer Conference Call Participants Joseph Catanzaro - Piper Sandler Charles Duncan - Cantor Fitzgerald Scott Henry - ROTH Capital Partners Joon Lee - Tr ...

Table of Contents Title of Each Class Ticker SymbolName of Exchange on Which Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Market Emerging Growth Company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission F ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2021 Earnings Conference Call November 10, 2021 8:30 AM ET Company Participants Patrick McEnany – Chairman and Chief Executive Officer Ali Grande – CFO Steven Miller – Chief Operating Officer and Chief Scientific Officer Jeffrey Del Carmen – Chief Commercial Officer Gary Ingenito – Chief Medical and Regulatory Officer Conference Call Participants Charles Duncan – Cantor Fitzgerald Scott Henry – ROTCE Capital Joseph – from Piper Sandler Joon Lee – Truist Operat ...

Table of Contents Title of Each ClassTicker SymbolName of Exchange on Which Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Market Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission ...